Results for "Specialty Pharmaceutical Distribution Facts, Figures, and Trends"
HDA Statement on Maryland Legislation Designed to Clarify Role of Critical Pharmacy Partners
The Healthcare Distribution Alliance (HDA) issued the following statement today from HDA Senior Vice President of State Government Affairs and Alliance Development Matt DiLoreto, upon introduction of SB 823 and HB 973 by the Maryland Legislature.
HDA’s Davis Shares 2022 Strategic Priorities Under Increased Awareness of Supply Chains
Events spanning COVID-19 vaccine distribution to shipping containers held up at port have made the supply chain a “kitchen-table” issue during the past year. Many industries experienced notable disruptions in their delivery of goods and supplies; however, as noted by President and CEO Chip Davis, “[P]harmacies, health systems and physicians’ offices, more than 180,000 across the country, remain stocked with the lifesaving medications and vaccines patients need. That didn’t happen by accident.” Davis’ perspective was featured alongside healthcare supply chain association leaders as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.
DSCSA, the 2023 Requirements and EPCIS
Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.
HDA Statement on Federal Trade Commission and Health and Human Services RFI on Drug Shortages
HDA commented on the release of an FTC and HHS Request for Information (RFI) investigating the causes of drug shortages.